174 related articles for article (PubMed ID: 32925563)
1. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.
Faiena I; Comin-Anduix B; Berent-Maoz B; Bot A; Zomorodian N; Sachdeva A; Said J; Cheung-Lau G; Pang J; Macabali M; Chodon T; Wang X; Cabrera P; Kaplan-Lefko P; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
J Immunother; 2020; 43(9):273-282. PubMed ID: 32925563
[TBL] [Abstract][Full Text] [Related]
2. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
3. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
Hernández JM; Bui MH; Han KR; Mukouyama H; Freitas DG; Nguyen D; Caliliw R; Shintaku PI; Paik SH; Tso CL; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 May; 9(5):1906-16. PubMed ID: 12738749
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J
J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus vaccine therapy with CD137L promotes CD8
Ding J; Jiang N; Zheng Y; Wang J; Fang L; Li H; Yang J; Hu A; Xiao P; Zhang Q; Chai D; Zheng J; Wang G
Pharmacol Res; 2022 Jan; 175():106034. PubMed ID: 34915126
[TBL] [Abstract][Full Text] [Related]
6. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
Simons JW; Jaffee EM; Weber CE; Levitsky HI; Nelson WG; Carducci MA; Lazenby AJ; Cohen LK; Finn CC; Clift SM; Hauda KM; Beck LA; Leiferman KM; Owens AH; Piantadosi S; Dranoff G; Mulligan RC; Pardoll DM; Marshall FF
Cancer Res; 1997 Apr; 57(8):1537-46. PubMed ID: 9108457
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
8. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
9. Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
Kim BR; Yang EK; Kim DY; Kim SH; Moon DC; Lee JH; Kim HJ; Lee JC
Clin Exp Immunol; 2012 Jan; 167(1):73-83. PubMed ID: 22132887
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.
Tani K; Azuma M; Nakazaki Y; Oyaizu N; Hase H; Ohata J; Takahashi K; OiwaMonna M; Hanazawa K; Wakumoto Y; Kawai K; Noguchi M; Soda Y; Kunisaki R; Watari K; Takahashi S; Machida U; Satoh N; Tojo A; Maekawa T; Eriguchi M; Tomikawa S; Tahara H; Inoue Y; Yoshikawa H; Yamada Y; Iwamoto A; Hamada H; Yamashita N; Okumura K; Kakizoe T; Akaza H; Fujime M; Clift S; Ando D; Mulligan R; Asano S
Mol Ther; 2004 Oct; 10(4):799-816. PubMed ID: 15451464
[TBL] [Abstract][Full Text] [Related]
11. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
13. Co-immunization with L-Myc enhances CD8
Chai D; Zhang Z; Jiang N; Ding J; Qiu D; Shi SY; Wang G; Fang L; Li H; Tian H; Yang J; Zhang Q; Zheng J
Cancer Sci; 2021 Sep; 112(9):3469-3483. PubMed ID: 34157192
[TBL] [Abstract][Full Text] [Related]
14. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
Figlin RA; Tannir NM; Uzzo RG; Tykodi SS; Chen DYT; Master V; Kapoor A; Vaena D; Lowrance W; Bratslavsky G; DeBenedette M; Gamble A; Plachco A; Norris MS; Horvatinovich J; Tcherepanova IY; Nicolette CA; Wood CG;
Clin Cancer Res; 2020 May; 26(10):2327-2336. PubMed ID: 32034074
[TBL] [Abstract][Full Text] [Related]
15. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
Höltl L; Zelle-Rieser C; Gander H; Papesh C; Ramoner R; Bartsch G; Rogatsch H; Barsoum AL; Coggin JH; Thurnher M
Clin Cancer Res; 2002 Nov; 8(11):3369-76. PubMed ID: 12429623
[TBL] [Abstract][Full Text] [Related]
18. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells.
Bleumer I; Tiemessen DM; Oosterwijk-Wakka JC; Völler MC; De Weijer K; Mulders PF; Oosterwijk E
J Immunother; 2007 Jan; 30(1):116-22. PubMed ID: 17198090
[TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
20. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]